Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072354 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 463
- Enrollment target
NCT04072354 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 463 participants.
The verdict
NCT04072354, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 463 participants
- Enrollment target
Study Summary
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who have been diagnosed with schizophrenia.
Interventions
- DRUG Placebo
- DRUG SEP-363856 75mg
- DRUG SEP-363856 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 463 participants |
| Start Date | 2019-09-17 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04072354
The ClinicalTrials.gov registry entry for NCT04072354 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04072354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04072354 about?
NCT04072354 is a clinical study titled "A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia". A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 13 years old -65 years old who ...
What is the current status of trial NCT04072354?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 463 participants. The study started on 2019-09-17. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT04072354?
The interventions under investigation include: Placebo (DRUG), SEP-363856 75mg (DRUG), SEP-363856 50mg (DRUG).
Who is sponsoring clinical trial NCT04072354?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.